India's Hetero says COVID-19 drug reduces hospitalisations in late-stage trial

Molnupiravir is an antiviral therapy Merck& Co is developing with Ridgeback Biotherapeutics for the treatment of non-hospitalised COVID-19 patients.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news